Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/Sh

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces the pricing of an underwritten public offering of 3,820,000 shares of its common stock at a public offering price of $22.25 per share. The gross proceeds to Rocket from the offering are expected to be $84,995,000, before deducting the underwriting discounts and commissions and other offering expenses. Rocket has granted the underwriters a 30-day option to purchase up to an additional 573,000 shares of its common stock.

All the shares in the offering are to be sold by Rocket. The offering is expected to close on or about December 13, 2019, subject to satisfaction of customary closing conditions. Rocket intends to use the net proceeds from this offering to further fund the development of its pipeline of gene therapies for rare diseases, to support the buildout of in-house manufacturing capabilities, and for general corporate purposes.

J.P. Morgan, Cowen and Evercore ISI are acting as the joint-bookrunning managers and LifeSci Capital LLC is acting as co-manager.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Ligand prices $625M convertible notes due 2031 at 0% interest